flaxseed extract

Overview

Flaxseed extract is a bioactive preparation derived from flaxseed, a plant source widely studied for its nutritional and functional properties. In biomedical and food-science contexts, flaxseed extract is of interest because it contains a mixture of compounds that can be incorporated into delivery systems to improve stability, handling, and potential bioavailability. Its research use often centers on formulation science rather than direct therapeutic use, with attention to how the extract behaves in complex matrices and under physiologic or processing conditions.

From a mechanistic perspective, flaxseed extract is being explored as a functional ingredient that can be encapsulated or otherwise engineered for controlled release. In the recent literature provided here, it was studied in relation to pH-responsive microcapsules built from sodium alginate and fish gelatin, indicating interest in protecting the extract and modulating its release behavior in response to environmental pH.

Focus of Latest Publications

The main flaxseed extract study provided was a food chemistry investigation of pH-responsive microcapsules designed for flaxseed extract encapsulation. The paper, titled “Molecular insights into the synergistic binding mechanism of flaxseed extract encapsulation within an alginate-fish gelatin matrix,” focused on developing a delivery system using a synergistic sodium alginate-fish gelatin matrix. The central research question was how flaxseed extract interacts with this matrix at the molecular level and how those interactions support microcapsule formation.

According to the publication context, the study used molecular dynamic and docking simulation to probe the binding mechanism between flaxseed extract and the encapsulating materials. The work emphasized the synergistic behavior of sodium alginate and fish gelatin in forming pH-responsive microcapsules, suggesting that the matrix was designed to respond to environmental pH changes and thereby modulate release characteristics. The reported emphasis was on encapsulation performance and molecular interactions, not on a disease model or therapeutic trial.

The other publication contexts supplied do not describe flaxseed extract as the primary experimental focus. They concern anemia management in chronic kidney disease, iron overload and ferroptosis in keratoconus, phosphorus and iron release from sludge, selenium and iron bioaccumulation in Pleurotus species, antioxidant nanomedicine in sepsis, and the cancer metallome. These studies are relevant only as broader contextual examples of how iron, reactive oxygen species, ferroptosis, mitochondrion-related injury, and related pathways are being investigated in biomedical research. No direct flaxseed extract-specific clinical or mechanistic conclusions can be drawn from those papers based on the information provided.

Key Publications

• NEWJul KDOQI US Commentary on the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD. (American journal of kidney diseases : the official journal of the National Kidney Foundation, 2026, PMID 42095795): "the proactive use of intravenous (IV) iron in hemodialysis patients and the preference for erythropoiesis stimulating agents (ESAs) over HIF-PHIs for first-line anemia therapy, due to greater familiarity with safety of the former."
• NEWJul Iron overload triggers pathological remodeling of corneal stroma through ferroptosis and senescence-associated secretory phenotype in keratoconus. (Redox biology, 2026, PMID 42217275): "Next, we confirmed significant iron accumulation and ferroptosis activation in both tissues and primary corneal stromal cells derived from KC patients."
• NEWJun Anaerobic release of phosphorus and iron from chemical phosphorus removal sludge increases in-plant recycles and creates recovery options. (Water science and technology : a journal of the International Association on Water Pollution Research, 2026, PMID 42301637): "Investigations identified the sources of highly variable solids-handling recycle phosphorus loading, averaging 35% of plant influent loading, but ranging above 100%."
• NEWJun Biofortified (Molecules (Basel, Switzerland), 2026, PMID 42357498): "This review explores the bioaccumulation potential of Pleurotus species of essential compounds of biotechnological interest, particularly selenium and iron, focusing on applications in sustainable nutrition and functional ingredient development."
• Jan Autophagy-ferroptosis crosstalk in sepsis: metabolic pathways, redox injury, and host-directed antioxidant nanomedicine. (Frontiers in immunology, 2026, PMID 42282965): "Building on this framework, we evaluated emerging antioxidant nanomedicines targeting key intervention points, including iron chelation, catalytic ROS/RNS scavenging, membrane-localised radical trapping, mitochondria-targeted source control, and enhancement of endogenous defences."
• Jun The Cancer Metallome Continuum: A Framework for Understanding Metal Dysregulation from Carcinogenesis to Therapeutic Resistance. (Metallomics : integrated biometal science, 2026, PMID 42360712): "For example, Fe accumulation can support tumour growth, while tumour cells concurrently engage anti-ferroptotic programs; Cu contributes to angiogenesis and kinase signalling, and Zn transporter networks regulate apoptosis and immune responses."
• May Molecular insights into the synergistic binding mechanism of flaxseed extract encapsulation within an alginate-fish gelatin matrix. (Food chemistry, 2026, PMID 41818991): "This study focused on the development of pH-responsive microcapsules for flaxseed (FE) extract using a synergistic sodium alginate-fish gelatin matrix."